002932 *ST明德生物
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入265,079-24.28%749,53710,530,2782,829,830959,099
减:营业总成本398,464-7.87%720,1464,497,1341,120,303405,651
    其中:营业成本169,2144.83%342,7033,491,170707,026208,995
               财务费用(1,058)-88.93%5,194(34,938)(5,880)(2,611)
               资产减值损失(13,323)-84.67%4,753(646,672)0--
公允价值变动收益(863)-149.72%4,5892,7600--
投资收益104,828-21.60%120,55035,1206731,310
    其中:对联营企业和合营企业的投资收益3,436-374.59%(6,735)--(5,776)(6,497)
营业利润(78,386)-290.32%145,1945,079,8331,697,814562,279
利润总额(63,794)-296.80%139,8895,076,3971,694,557556,701
减:所得税费用11,26892.57%70,673695,843247,86981,073
净利润(75,062)-382.56%69,2164,380,5541,446,688475,628
减:非控股权益(58,601)22.20%(5,710)172,05733,4636,700
股东净利润(16,461)-122.09%74,9264,208,4971,413,224468,928

市场价值指针
每股收益 (元) *-0.070-121.21%0.33018.4609.9504.990
每股派息 (元) *----0.1205.2004.5002.000
每股净资产 (元) *----25.91541.61526.59115.967
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见----
回页顶
备注: *未调整数据
#只提供简体内容